Pharma major Lupin Limited (Lupin) announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit III) facility, India.

Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, is the generic equivalent of Diprolene® Ointment, 0.05%, of Merck Sharp and Dohme Corp. It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.

Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, (RLD: Diprolene®) had an annual sales of approximately USD 21 million in the U.S. (IQVIA MAT January 2020).